Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer

Barbara L. Fowble, John P. Einck, Danny N. Kim, Susan McCloskey, Jyoti Mayadev, Catheryn Yashar, Steven L. Chen, E. Shelley Hwang

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Purpose: To identify a cohort of women treated with neoadjuvant chemotherapy and mastectomy for whom postmastectomy radiation therapy (PMRT) may be omitted according to the projected risk of local-regional failure (LRF). Methods and Materials: Seven breast cancer physicians from the University of California cancer centers created 14 hypothetical clinical case scenarios, identified, reviewed, and abstracted the available literature (MEDLINE and Cochrane databases), and formulated evidence tables with endpoints of LRF, disease-free survival, and overall survival. Using the American College of Radiology appropriateness criteria methodology, appropriateness ratings for postmastectomy radiation were assigned for each scenario. Finally, an overall summary risk assessment table was developed. Results: Of 24 sources identified, 23 were retrospective studies from single institutions. Consensus on the appropriateness rating, defined as 80% agreement in a category, was achieved for 86% of the cases. Distinct LRF risk categories emerged. Clinical stage II (T1-2N0-1) patients, aged >40 years, estrogen receptor-positive subtype, with pathologic complete response or 0-3 positive nodes without lymphovascular invasion or extracapsular extension, were identified as having ≤10% risk of LRF without radiation. Limited data support stage IIIA patients with pathologic complete response as being low risk. Conclusions: In the absence of randomized trial results, existing data can be used to guide the use of PMRT in the neoadjuvant chemotherapy setting. Using available studies to inform appropriateness ratings for clinical scenarios, we found a high concordance of treatment recommendations for PMRT and were able to identify a cohort of women with a low risk of LRF without radiation. These low-risk patients will form the basis for future planned studies within the University of California Athena Breast Health Network.

Original languageEnglish (US)
Pages (from-to)494-503
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume83
Issue number2
DOIs
StatePublished - Jun 1 2012

Keywords

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Postmastectomy radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Fowble, B. L., Einck, J. P., Kim, D. N., McCloskey, S., Mayadev, J., Yashar, C., Chen, S. L., & Hwang, E. S. (2012). Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. International Journal of Radiation Oncology Biology Physics, 83(2), 494-503. https://doi.org/10.1016/j.ijrobp.2012.01.068